Kilitch Drugs approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, with auditors issuing unmodified opinions.
Standalone FY26 net profit increased to ₹32.40 crore from ₹31.16 crore YoY, while revenue grew to ₹188.57 crore from ₹181.59 crore.
The company issued a 1:1 bonus share allotment of 1.74 crore equity shares on March 25, 2026, doubling its paid-up capital.
Consolidated FY26 performance showed net profit attributable to owners of ₹30.17 crore on revenue of ₹235.47 crore.